期刊
PEDIATRIC RADIOLOGY
卷 52, 期 4, 页码 693-701出版社
SPRINGER
DOI: 10.1007/s00247-021-05206-5
关键词
6-fluoro-(F-18)-L-3; 4-dihydroxyphenylalanine; Congenital hyperinsulinism; Hyperinsulinism; Neonates; Pancreas; Positron emission tomography
Hyperinsulinemic hypoglycemia of infancy, also known as congenital hyperinsulinism, is a group of disorders characterized by dysregulated insulin release. Severe cases may require pancreatectomy to prevent brain damage from hypoglycemia, and surgical resection of a focal lesion can result in a cure in up to 97% of children. PET imaging with genetic evaluation is crucial for guiding surgical treatment.
Hyperinsulinemic hypoglycemia of infancy, also known as congenital hyperinsulinism, is a group of disorders characterized by dysregulated insulin release. Neonates with severe, persistent hyperinsulinemic hypoglycemia who are unresponsive to medical therapy require pancreatectomy to prevent brain damage from hypoglycemia. To date, multiple genetic mutations and syndromes and several unique histopathological entities have been identified in children with hyperinsulinism. Histopathology is characterized as diffuse, focal or atypical. Surgical resection of a focal lesion results in a cure in up to 97% of these children. Imaging with 6-fluoro-(F-18)-L-3,4-dihydroxyphenylalanine (F-18-FDOPA) positron emission tomography (PET) is the test of choice for identifying and localizing a focal lesion and has proved to be an invaluable guide for surgical resection. Genetic evaluation is essential for determining who will benefit from PET imaging. This article provides an approach to determine who should be imaged, how to set up a protocol and how to interpret the imaging findings. The diagnosis and management of this disorder require a multidisciplinary approach to prevent brain damage from hypoglycemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据